A Local, Sustained Delivery System for Zoledronic Acid and RANKL-Inhibitory Antibody as a Potential Treatment for Metastatic Bone Disease
Cancerous solid tumors can migrate and lead to metastatic bone disease. Drugs prescribed to reduce bone resorption from metastasis, such as zoledronic acid and the RANKL-inhibitory antibody Denosumab, cause side effects such as osteonecrosis of the jaw when delivered systemically. This project used...
| Main Author: | |
|---|---|
| Format: | Others |
| Published: |
UKnowledge
2015
|
| Subjects: | |
| Online Access: | http://uknowledge.uky.edu/cbme_etds/34 http://uknowledge.uky.edu/cgi/viewcontent.cgi?article=1037&context=cbme_etds |